Cardiovascular · StatinRegulatory Approvalregulatorymid-term

FDA Accepts Supplement for Rosuvastatin Calcium by Macleods

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Macleods Pharmaceuticals11 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/24/2026, 12:30:59 AM

Assessment confidence: 63% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The FDA's acceptance of Macleods' supplemental application for Rosuvastatin Calcium is a significant regulatory milestone that could shift competitive dynamics in the statin market. Portfolio teams must evaluate the implications for market share and pricing strategies among existing products as competition intensifies. Regulatory context from FDA (FDA AP — CRESTOR (SUPPL)) supports the near-term read. Assessment grounded in 23 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing statin products. The strongest clinical anchor is Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using Low Specific Absorption Rate (SAR) Scanner System (ClinicalTrials.gov), mechanism alignment (io ). In Cardiovascular · Statin, 8 regulatory and 2 competitive items passed relevance filtering for Macleods Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Accepts Supplemental NDA for Linzess by AbbVie. This acceptance may enhance Macleods' position in the statin market, potentially increasing competition against established players.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — CRESTOR (SUPPL) (FDA). Sponsor/company relevance (AstraZeneca). The acceptance of this supplemental application indicates a positive regulatory trajectory for Macleods, but the final approval timeline remains critical to assess.

Key Risks

Elevated medium regulatory exposure for Macleods Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose) could weigh on Macleods Pharmaceuticals through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

If Macleods successfully enters the market with Rosuvastatin Calcium, it could pressure pricing and market share for established competitors, potentially affecting revenue streams.
Upside for Macleods Pharmaceuticals may improve if Cost-effectiveness and budget impact of ezetimibe-atorvastatin single-pill combination versus free combination in Chinese adults with hypercholesterolemia. (PubMed) delivers favorable follow-through.
Upside for Macleods Pharmaceuticals may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing statin products.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for final approval and any subsequent market entry strategies from Macleods.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — CRESTOR (SUPPL)
FDAhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA AP — ROSUVASTATIN CALCIUM (SUPPL)
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA AP — AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — ATORVASTATIN CALCIUM (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using Low Specific Absorption Rate (SAR) Scanner System
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Validate the Effect of Calcium Oral Spray on Early Childhood Caries
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Physical Fitness, Cardiovascular and Brain Health
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts Supplemental NDA for Linzess by AbbVie
Humanexa Signalsmedium relevance
Moderate corpus alignment

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Effect of oral calcium carbonate on uterine contractility: a pilot randomised controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Cost-effectiveness and budget impact of ezetimibe-atorvastatin single-pill combination versus free combination in Chinese adults with hypercholesterolemia.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Optimizing estradiol serum levels for optimal skeletal and cardiovascular health during transdermal menopausal hormone therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Macleods Pharmaceuticals
established players

Commercial impact

medium

If Macleods successfully enters the market with Rosuvastatin Calcium, it could pressure pricing and market share for established competitors, potentially affecting revenue streams.

Regulatory impact

medium

The acceptance of this supplemental application indicates a positive regulatory trajectory for Macleods, but the final approval timeline remains critical to assess.

What to watch

Monitor the timeline for final approval and any subsequent market entry strategies from Macleods.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.